Beyond Weight Loss: GLP-1 Cardiovascular and Kidney Data
GLP-1 evidence extends beyond weight loss: SELECT showed semaglutide cut cardiovascular events ~20%, and FLOW showed it slowed kidney disease progression in type 2 diabetes. These benefits apply to the approved products, not compounded versions. These organ-protection findings apply to the FDA-approved products in the specific populations studied, not to compounded versions and not automatically to everyone; tirzepatide's own cardiovascular and kidney outcome trials are still underway.
- SELECT: semaglutide cut major cardiovascular events ~20% (CVD, no diabetes).
- FLOW: semaglutide slowed chronic kidney disease progression in type 2 diabetes.
- SUSTAIN and other trials support cardiovascular benefit in diabetes.
- These organ-protection findings apply to approved products only.
The cardiovascular evidence
The most prominent non-weight benefit is cardiovascular. The SELECT trial showed semaglutide 2.4mg reduced major adverse cardiovascular events by about 20% in adults with cardiovascular disease and overweight or obesity, without diabetes.
Earlier trials in people with type 2 diabetes, including the SUSTAIN cardiovascular outcomes program, also demonstrated cardiovascular benefit. Together these established semaglutide as more than a weight or glucose drug.
The benefit appears only partly explained by weight loss, suggesting direct cardiovascular effects.
The kidney evidence
The FLOW trial studied semaglutide in people with type 2 diabetes and chronic kidney disease and found it slowed the progression of kidney disease and reduced kidney-related events. This is a meaningful finding, because kidney disease is a major complication of diabetes with few effective drug options.
The kidney benefit adds to the cardiovascular data, painting a picture of organ protection that extends beyond the drug's effect on weight and glucose.
As with the cardiovascular data, this evidence is for the approved product in the studied population.
| Trial | Population | Finding |
|---|---|---|
| SELECT | CVD + overweight/obesity, no diabetes | ~20% fewer cardiac events |
| FLOW | Type 2 diabetes + CKD | Slowed kidney disease |
| SUSTAIN CVOT | Type 2 diabetes | Cardiovascular benefit |
How to interpret organ-protection data
These findings are important but specific. Each applies to a defined population: SELECT to CVD patients with overweight/obesity without diabetes, FLOW to diabetes patients with kidney disease. The benefits are most directly applicable to people resembling those groups.
It is not valid to assume every person taking a GLP-1 gets the same cardiovascular or kidney protection, nor that the benefits transfer to tirzepatide automatically, though tirzepatide has its own outcomes trials underway.
Relative risk reductions also translate to smaller absolute differences, though across high-risk populations the events prevented are substantial.
Why compounded products are excluded
Every one of these organ-protection findings was demonstrated with an FDA-approved product manufactured to a defined standard. Compounded semaglutide has no cardiovascular or kidney outcome data of its own.
Assuming the SELECT or FLOW benefits transfer to a compounded formulation is not evidence-based. The molecule may match, but the outcome evidence attaches to the studied product.
For a patient whose goal includes cardiovascular or kidney protection, this is a specific reason to discuss the approved product with a clinician.
| Applies to | Does not apply to |
|---|---|
| Approved semaglutide products | Compounded semaglutide |
| Studied populations | Everyone automatically |
The bottom line
GLP-1 benefits extend beyond weight loss: semaglutide reduced cardiovascular events (~20% in SELECT) and slowed kidney disease progression (FLOW), with additional diabetes cardiovascular data.
These organ-protection findings apply to approved products in defined populations, not to compounded versions or automatically to everyone. Tirzepatide's own outcome trials are ongoing.
If organ protection is a goal, that is a reason to discuss the approved product with your clinician.
Frequently asked questions
What cardiovascular benefit does semaglutide have?
In SELECT, semaglutide 2.4mg reduced major cardiovascular events by about 20% in adults with cardiovascular disease and overweight or obesity, without diabetes.
Does semaglutide protect the kidneys?
The FLOW trial showed semaglutide slowed chronic kidney disease progression in people with type 2 diabetes and kidney disease.
Do these benefits apply to compounded semaglutide?
No. They were demonstrated with approved products. Compounded semaglutide has no cardiovascular or kidney outcome data.
Does tirzepatide have the same organ data?
Tirzepatide has its own outcomes trials underway. The semaglutide findings do not automatically transfer to it.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, FLOW trial publications.
- ClinicalTrials.gov and prescribing information.
- Evidence policy: evidence policy.